Enanta declines option on AbbVie-partnered hepatitis C candidate
This article was originally published in Scrip
Executive Summary
Just weeks after Novartis abandoned hepatitis C and returned all rights to EDP239, an NS5A inhibitor currently in Phase I to Enanta Pharmaceuticals (scripintelligence.com, 2 October 2014), the smaller company has decided not to exercise its co-development option for AbbVie's ABT-493.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.